Haemonetics (NYSE:HAE) Downgraded to “Hold” Rating by Wall Street Zen

Haemonetics (NYSE:HAE) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other equities analysts have also commented on HAE. Weiss Ratings reissued a “hold (c-)” rating on shares of Haemonetics in a report on Monday, December 8th. Citigroup cut their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Raymond James Financial restated an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Needham & Company LLC increased their price target on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $80.90.

Haemonetics Stock Down 1.2%

HAE stock opened at $83.46 on Friday. The company’s 50 day moving average price is $65.38 and its 200 day moving average price is $64.42. The firm has a market capitalization of $3.91 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 1.58 and a beta of 0.30. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the previous year, the business posted $1.12 EPS. The firm’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities research analysts anticipate that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares during the period. Quarry LP grew its holdings in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 192 shares during the last quarter. UMB Bank n.a. increased its position in Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 320 shares during the period. Finally, Versant Capital Management Inc raised its stake in Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.